Elemental Formula Sales Surge with Growing Shift to Hypoallergenic Solutions, finds Fact.MR Study

NEXT STORY
SELLAS Life Sciences Announces Presentation of Final Data Analysis from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2019 ASCO-SITC Clinical Immuno-Oncology Meeting
PREV STORY
Novo Nordisk: Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

author_avatar
NASDAQ Market News

Oncorus to Host Investor Day Featuring its IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Platform and Lead Synthetic vRNA Product Candidates

author_avatar
NASDAQ Market News

New Lacutamab Data From Tellomak Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma

author_avatar
NASDAQ Market News